A citation-based method for searching scientific literature

Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
Times Cited: 122







List of co-cited articles
1100 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
320
52

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
535
50

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
230
47


Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge,[...]. Ann Rheum Dis 2014
312
46

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
687
42

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
276
42

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
259
41

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
525
40

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Eric Lespessailles, Stephen Hall, Marla Hochfeld, ChiaChi Hu,[...]. Ann Rheum Dis 2014
294
40

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
545
39

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
690
36

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
505
36

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
542
34

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthur Kavanaugh, Iain McInnes, Philip Mease, Gerald G Krueger, Dafna Gladman, Juan Gomez-Reino, Kim Papp, Julie Zrubek, Surekha Mudivarthy, Michael Mack,[...]. Arthritis Rheum 2009
448
34

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Jacob Aelion, Randall M Stevens, Adele Vessey, Xiaojiang Zhan, Paul Bird. Ann Rheum Dis 2016
159
32

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha,[...]. Ann Rheum Dis 2016
591
28

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E Furst, Jerry Molitor, Edward Keystone, Dafna Gladman,[...]. Arthritis Rheum 2005
487
28

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
154
28

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu,[...]. J Rheumatol 2016
119
27

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia. Arthritis Rheumatol 2017
67
40

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
622
25

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
P J Mease, B S Goffe, J Metz, A VanderStoep, B Finck, D J Burge. Lancet 2000
24

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Philip Mease, Mark C Genovese, Geoffrey Gladstein, Alan J Kivitz, Christopher Ritchlin, Paul P Tak, Jürgen Wollenhaupt, Orna Bahary, Jean-Claude Becker, Sheila Kelly,[...]. Arthritis Rheum 2011
216
23

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Philip J Mease, Mark C Genovese, Maria W Greenwald, Christopher T Ritchlin, André D Beaulieu, Atul Deodhar, Richard Newmark, JingYuan Feng, Ngozi Erondu, Ajay Nirula. N Engl J Med 2014
277
20

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia. Lancet 2018
105
20

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
Philip J Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, James B Chung. Arthritis Rheumatol 2019
99
20

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
18

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
117
18

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
113
18

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Mark C Genovese, Philip J Mease, Glen T D Thomson, Alan J Kivitz, Renee J Perdok, Mark A Weinberg, John Medich, Eric H Sasso. J Rheumatol 2007
151
17

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
Laura C Coates, Anna R Moverley, Lucy McParland, Sarah Brown, Nuria Navarro-Coy, John L O'Dwyer, David M Meads, Paul Emery, Philip G Conaghan, Philip S Helliwell. Lancet 2015
274
16



The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Philip J Mease, Alice B Gottlieb, Alberto Berman, Edit Drescher, Jun Xing, Robert Wong, Subhashis Banerjee. Arthritis Rheumatol 2016
105
15

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Peter Nash, Philip J Mease, Iain B McInnes, Proton Rahman, Christopher T Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu,[...]. Arthritis Res Ther 2018
75
20

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Elizabeth G Araujo, Matthias Englbrecht, Sabrina Hoepken, Stephanie Finzel, Eleni Kampylafka, Arnd Kleyer, Sarah Bayat, Verena Schoenau, Axel Hueber, Juergen Rech,[...]. Semin Arthritis Rheum 2019
69
21

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
114
15

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Maria Paris, Lichen Teng, Jacob A Aelion. Rheumatology (Oxford) 2018
44
31

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
Jonathan P Sherlock, Barbara Joyce-Shaikh, Scott P Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M Gorman, Edward P Bowman, Terrill K McClanahan, Jennifer H Yearley,[...]. Nat Med 2012
711
13

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
Gabrielle H Kingsley, Anna Kowalczyk, Helen Taylor, Fowzia Ibrahim, Jonathan C Packham, Neil J McHugh, Diarmuid M Mulherin, George D Kitas, Kuntal Chakravarty, Brian D M Tom,[...]. Rheumatology (Oxford) 2012
220
13

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Arthur Kavanaugh, Désirée van der Heijde, Iain B McInnes, Philip Mease, Gerald G Krueger, Dafna D Gladman, Juan Gómez-Reino, Kim Papp, Anna Baratelle, Weichun Xu,[...]. Arthritis Rheum 2012
160
13

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
P J Mease, P Ory, J T Sharp, C T Ritchlin, F Van den Bosch, F Wellborne, C Birbara, G T D Thomson, R J Perdok, J Medich,[...]. Ann Rheum Dis 2009
195
13

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
Peter Nash, Kamal Ohson, Jessica Walsh, Nikolay Delev, Dianne Nguyen, Lichen Teng, Juan J Gómez-Reino, Jacob A Aelion. Ann Rheum Dis 2018
48
27

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
95
13

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
327
13

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Georg Schett, Jurgen Wollenhaupt, Kim Papp, Rik Joos, Jude F Rodrigues, Adele R Vessey, ChiaChi Hu, Randall Stevens, Kurt L de Vlam. Arthritis Rheum 2012
149
12

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
12

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
434
12

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
Arthur Kavanaugh, Iain B McInnes, Philip J Mease, Stephen Hall, Hector Chinoy, Alan J Kivitz, Zailong Wang, Shephard Mpofu. J Rheumatol 2016
61
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.